Bank Julius Baer & Co
MCRB icon

Bank Julius Baer & Co’s Seres Therapeutics MCRB Stock Holding History

Bank Julius Baer & Co’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,812
Closed -$252K – 867
2021
Q3 		$252K Sell
1,812
-263
-13% -$51.5K ﹤0.01% 523
2021
Q2 		$990K Buy
2,075
+562
+37% +$237K 0.01% 348
2021
Q1 		$623K Buy
1,513
+213
+16% +$98.1K ﹤0.01% 407
2020
Q4 		$637K Buy
+1,300
New +$761K 0.01% 418

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank Julius Baer & Co's MCRB Position: Q4 2021 in Review

Bank Julius Baer & Co sold out of Seres Therapeutics (MCRB) in Q4 2021, closing a stake of 1,812 shares — an estimated $252K sold.

Bank Julius Baer & Co first reported a position in MCRB in Q4 2020 and held it in 4 quarters. The position peaked at $990K in Q2 2021. 148 funds tracked by Wall St. Rank hold MCRB as of Q4 2021.

  • Bank Julius Baer & Co reported no remaining Seres Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 1,812 Seres Therapeutics shares in Q4 2021, an estimated $252K.
  • Bank Julius Baer & Co first reported a position in Seres Therapeutics in Q4 2020 and held it in 4 quarters.
  • Bank Julius Baer & Co's Seres Therapeutics position peaked at $990K in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2021.

Based on Bank Julius Baer & Co's 13F filing for Q4 2021, filed 15 Feb 2022.